v3.26.3
Sale of Future IMDELLTRA® Royalties - Schedule of Royalty Sale Liability Activity (Details)
$ in Thousands
9 Months Ended
Sep. 30, 2026
USD ($)
Royalty Financing Obligation [Roll Forward]  
Balance at December 31, 2025 $ 3,827,379
Balance at September 30, 2026 4,055,531
Royalty Payments  
Royalty Financing Obligation [Roll Forward]  
Balance at December 31, 2025 906,956
Debt portion of royalties recognized and settled to Royalty Pharma (2,556)
Accretion of liability 8,181
Balance at September 30, 2026 $ 912,581